Biomimetic nanomedicines for precise atherosclerosis theranostics.
10.1016/j.apsb.2022.11.014
- Author:
Ying TAO
1
;
Xinmiao LAN
2
;
Yang ZHANG
3
;
Chenxing FU
4
;
Lu LIU
5
;
Feng CAO
3
;
Weisheng GUO
1
Author Information
1. Department of Minimally Invasive Interventional Radiology, Key Laboratory of Molecular Target & Clinical Pharmacology, School of Biomedical Engineering & the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.
2. School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
3. Department of Cardiology, the Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.
4. Department of Cardiology and Laboratory of Heart Center, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
5. Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR 999077, China.
- Publication Type:Review
- Keywords:
Active targeting;
Atherosclerosis;
Biomimetic nanomedicines;
Diagnosis and treatment;
Drug delivery;
Nanotheranostics;
Passive targeting;
Plaques
- From:
Acta Pharmaceutica Sinica B
2023;13(11):4442-4460
- CountryChina
- Language:English
-
Abstract:
Atherosclerosis (AS) is a leading cause of the life-threatening cardiovascular disease (CVD), creating an urgent need for efficient, biocompatible therapeutics for diagnosis and treatment. Biomimetic nanomedicines (bNMs) are moving closer to fulfilling this need, pushing back the frontier of nano-based drug delivery systems design. This review seeks to outline how these nanomedicines (NMs) might work to diagnose and treat atherosclerosis, to trace the trajectory of their development to date and in the coming years, and to provide a foundation for further discussion about atherosclerotic theranostics.
